Ceryvyn Therapeutics (ASX:CYV) Selling, General, & Admin. Expense: A$32.21 Mil (TTM As of Jun. 2025)


What is Ceryvyn Therapeutics Selling, General, & Admin. Expense?

Ceryvyn Therapeutics ASX:CYV -7.69% Selling, General, & Admin. Expense is A$32.21 Mil as of Jun. 2025. The stock has 3 warning signs investors should review.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Ceryvyn Therapeutics's selling, general, & admin. expense for the six months ended in Jun. 2025 was A$7.66 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Jun. 2025 was A$32.21 Mil.

Ceryvyn Therapeutics  (ASX:CYV) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.

Ceryvyn Therapeutics Selling, General, & Admin. Expense Related Terms

Ceryvyn Therapeutics Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for Ceryvyn Therapeutics's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ceryvyn Therapeutics Selling, General, & Admin. Expense Chart

Ceryvyn Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.54 19.35 19.04 19.23 31.55

Ceryvyn Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.02 10.01 9.14 24.55 7.66

ASX:CYV vs VRTX, REGN, ALNY: Selling, General, & Admin. Expense Comparison

For the Biotechnology subindustry, Ceryvyn Therapeutics's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ceryvyn Therapeutics Selling, General, & Admin. Expense vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ceryvyn Therapeutics's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Ceryvyn Therapeutics's Selling, General, & Admin. Expense falls into.


Ceryvyn Therapeutics Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$32.21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of A$32.21 Mil mean?
Ceryvyn Therapeutics (ASX:CYV) has a Selling, General, & Admin. Expense of A$32.21 Mil as of Jun. 2025. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Ceryvyn Therapeutics and its competitors.
Is Ceryvyn Therapeutics' Selling, General, & Admin. Expense too high?
Ceryvyn Therapeutics' current Selling, General, & Admin. Expense is A$32.21 Mil.
How does Ceryvyn Therapeutics' Selling, General, & Admin. Expense compare to VRTX and REGN?
Ceryvyn Therapeutics' Selling, General, & Admin. Expense of A$32.21 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Biotechnology company?
A good Selling, General, & Admin. Expense depends on the Biotechnology industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Ceryvyn Therapeutics and its competitors. Ceryvyn Therapeutics's current Selling, General, & Admin. Expense is A$32.21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ceryvyn Therapeutics stock overvalued right now?
Ceryvyn Therapeutics (ASX:CYV) has a current Selling, General, & Admin. Expense of A$32.21 Mil. The current Selling, General, & Admin. Expense is A$32.21 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Ceryvyn Therapeutics (ASX:CYV), the current Selling, General, & Admin. Expense is A$32.21 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ceryvyn Therapeutics Business Description

Address C/ Prime Company Compliance, 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.